Stephen Clark
@SClarkPharmD
Followers
460
Following
1K
Media
42
Statuses
1K
Oncology Clinical Pharmacy Specialist. Views expressed are mine alone. Follow ≠ endorsement.
Chapel Hill, NC
Joined November 2011
Maintenance Therapy in AML: A Trailblazing Slam Dunk, or a Flagrant Fowl. Always a pleasure to hear @ajperissinotti @Berninini. What a lively and engaging debate! #HOPA2025
0
3
13
Epinephrine nasal spray for anaphylaxis now FDA approved. https://t.co/VbRKfHkJBE
webmd.com
WebMD provides the basics on allergies – what they are and why some people have them.
0
0
1
The publication on which Blinatumomab received FDA approval for use in consolidation in MRD- ALL is now available!
nejm.org
Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination chemoth...
0
0
2
#HOPA Next Big Idea: If anyone is interested in a brainstorming session I'm happy to organize. I especially want my colleagues with smaller networks or internal teams to have an opportunity. @HOPArx
https://t.co/ukqmFA2zu9
0
0
4
Using the term "non-creative" instead of "palliative" treatment when communicating with patients can help improve communication. https://t.co/QeO6BVSfGU
academic.oup.com
This commentary explores the language choices that oncology providers make when discussing cancer therapy goals.
2
1
3
FDA approves lifileucel. It's the first CAR-T treatment approved for metastatic melanoma and also the first CAR-T I was able to pronounce on the first attempt. https://t.co/cY8Snh1OMg
0
1
11
"Ivosidenib significantly reduced posaconazole and voriconazole levels. Vori should be avoided, empiric high-dose posa (>300 mg/day) may be considered, and therapeutic drug monitoring is recommended in all patients receiving concomitant ivosidenib." @Benyam_Muluneh @KatieBPharmD
0
5
12
FDA approves Omalizumab to reduce accidental food allergies. It's a SQ injection dosed every 2-4 weeks. https://t.co/7njkYrNDKl
0
0
2
🚨NEW POD ALERT🚨 Burnout and Well-being 🧯 ft. Brent Reed @brentnreed How did we get here? 🛣️ Prevention v. treatment ⚔️ Work:life balance ⚖️ Foundation of burnout prevention 🏠 5 step process for work design change 🖐️ & more! https://t.co/7UAx7hR7DJ
https://t.co/aV7jenhxsU
0
8
24
Castlemans disease treatment discovered with the help of AI. Too early to tell how effective it is but so far it has helped at one person. https://t.co/GpCaHsIfOu
1
0
2
Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia - Nice work, James B Collins, @Benyam_Muluneh @sarahstump1! 2023
journals.sagepub.com
Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for chronic myeloid leukemia (CML). Patients enrolled in clinical trials investigating the safet...
0
0
8
The ACORN investigators leveraged their EHR to enroll patients for clinical trial of cefepime vs pip-tazo. Brilliant execution when speed was essential.
The ACORN study of cefepime vs pip-tazo serves as a great lesson in how to do randomized trials in hospitalized patients. Now that we have this model, let's do more of this, please! Here's why it's so important: https://t.co/6ti2xxuYRa
0
0
6
Dana-Farber is leaving Brigham and Women's (eventually)
Now begins the most awkward period in any relationship: When 1 person dumps the other but they still have to live together for 5 years until the lease runs out…
0
0
0
BREAKING NEWS The 2023 #NobelPrize in Physiology or Medicine has been awarded to Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
4K
26K
73K
So pleased to report that our Mount Sinai-Yale long COVID (MY-LC) paper with @putrinolab & others is now published!! Proud of the hard work of all who contributed. We found biological signatures that can distinguish people with vs. without #longCOVID (1/)
nature.com
Nature - Individuals with long COVID show marked biological changes in cortisol and immune factors relative to convalescent populations.
130
2K
6K
Most of these are based on actual denials! https://t.co/aG6RcthRWg
0
0
1
Very excited to launch the Yale Center for Infection and Immunity @YaleCII focused on unraveling the disease pathogenesis of post-acute infection syndromes and making effective vaccines to prevent infectious diseases. #longCOVID #MECFS #chronicLyme
https://t.co/TySVplQAlm
yaledailynews.com
The Yale School of Medicine’s new Center for Infection & Immunity, which launched on Aug. 18, is researching post-acute infection syndromes while encouraging diversity, elevating scientists and...
98
498
2K
A fresh perspective on prior auth solutions. https://t.co/BYTlQYgtFC
medscape.com
Ravi B. Parikh, MD, MPP, explores the growing burden of prior authorization, why it's happening, and how we can start to fix it from the inside.
0
1
1